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ABSTRACT: Epilepsy is the most common neurological disorder. The term epilepsy serves as 
an umbrella term to describe any faulty mechanism in the brain that causes an electrical storm, 
resulting in a seizure. These malfunctions may include problems with sodium channels, calcium 
channels, or with cell to cell interactions. Also, ensemble interactions play a role. Currently, 
there are various treatments which include medication, diet, surgery, and also an implantable 
device. 
Other pertinent issues with epilepsy deal with social aspects. Sexual dysfunction is 
prevalent in epileptics. Epileptic women need to be aware of fertility problems. In addition, 
catamenial epilepsy affects many epileptic women. Pregnancy difficulties result both from the 
seizures themselves and from the teratogenicity of the medications. Sudden, unexplained death is 
also prevalent in epileptics. Also, memory problems are often associated with this condition. In 
addition, medication costs can plague epileptics. 
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Mechanisms of Epileptic Seizures 
Epilepsy is the most common neurological disorder. It is presumed to affect from 
one half of one percent to one percent of the population. Epilepsy is a broad diagnosis for 
a number of neurological misfunctions that manifest themselves as different types of 
seizures. This chapter explores the possible causes of seizures. 
Epileptic seizure can be characterized by two primary features, both of which are 
sufficient to produce seizure activity by themselves. The first is hyperexcitability of 
multiple neurons within a population. As will be shown, most of the means to produce 
this effect are normal basic mechanisms that have been deregulated. The second is 
hypersynchrony. Petit mal epilepsy is a common example of a clinical syndrome in 
which epilitiform activity involves primarily hypersynchonization. The abnormal 
discharge appears to result from a synchrony of widespread cell populations so great as to 
wipe out any functionally significant signals that might enter the central nervous system.! 
An important component of the nervous system is its plasticity, the basic 
mechanism that supports change. However, this component can produce 
hyperexcitability and hypersynchrony that characterize epileptiform activities. Brain 
regions, such as the cortical structures, with best preparedness for plastic responses are 
most likely to be the focus of epileptiform activity. Three contributions to epilepsy's 
irregular neuronal function are intrinsic cell properties, cell-to-cell interactions, and 
ensemble interactions. 2 
There is great debate over whether there are "epileptic neurons" in populations of 
cells. These neurons were thought to be cells with "intrinsic abnormalities that drove the 
activity of normal neurons."3 No cells with such qualities have been located by 
researchers. However, scientists feel that there must be some abnormality at the single-
cell level. Because many factors influence the cell's excitability, isolation in a research 
environment can show little evidence of being intrinsically epileptic.4 
In the electronic structure of the molecule, recent studies have shown that 
synapses located closer to the initial segment have more powerful effects than synapses at 
more distant processes. This demonstration has caused much optimism in the field of 
neurology because the epileptic brain's cells may only have proximal dendrites. This 
structural change could contribute significantly to altering the transfer of synaptic current. 
In instances of abnormal increased activity, a small morphologic alteration has been 
found by researchers. This change could quite possibly explain the positive feedback that 
most epileptics experience.5 
The depolarization of the membrane causes the opening of the sodium channel. 
This depolarization forms the upstroke of the action potential. These channels inactivate 
quickly and then no longer allow ionic flux. Thus when a neuron is significantly 
depolarized, spiking may quickly fade away. Repetition of discharge is critical to a cell's 
abiltiy to participate in an aggregate of hyperexcitable neurons.6 
In addition to this inactivating sodium current, a noninactivating sodium current 
has been found in many pyramidal neurons. Opening of this channel occurs with only 
small amounts of depolarization (from resting potential), and the current contributes in 
subtle, but important ways to the pattern of cell activity. For example, if the excitatory 
postsyanptic potential (EPSP)-induced depolarization is sufficient to open the 
noninactivating sodium channels, the depolarization booster mechanism is relatively 
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long-lasting because the current is noninactivating, and may be sufficient to bring 
subthreshold depolarizations to a suprathreshold level to initiate spike discharge.? 
Calcium channels are divided into three categories. The first, the T -type channel, 
is considered low-threshold and is thought to help to synchronize cell populations. This 
channel can cause a burst of action potentials when it opens to admit calcium. This 
opening will further depolarize the cell. Some Petit mal seizures have been known to 
originate in deformities at these channels.8 
Another type of calcium channel (L-type) remains closed at resting potential. It 
opens when the cell is depolarized by a great number of millivolts. The voltage-
dependent calcium influx may add significantly to the depolarization. Summation can 
generate the burst discharges. The final channel is the N-type, whose role in the 
postsynaptic cell is unclear.9 
Neurotransmitter is dependent on the voltage-dependent conductance in terminal 
membrane. N-type calcium channels contribute to the calcium influx while potassium 
repolarizes the cell membrane to prevent too much calcium from entering. The level and 
pattern of activity in single elements of a large interconnected population significantly 
affect the pattern of discharge in the population as a whole. Therefore, the epileptiform 
discharge is more likely when there is an increase in the level of excitability at the single-
cell level, like in cases of spontaneous excitatory transmitter release. IO 
Cell-to-cell interaction can range from chemical transmission to ephaptic 
interaction. Modification of either of these activities can result in epileptogenesis. The 
loss of GABAergic inhibition is the foundation for a long held hypothesis in epileptiform 
activity. GABA is the primary inhibitory neurotransmitter in cortical structures. GABA-
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a receptors mediate the inhibitory postsynaptic potentials (IPSPs). Binding of GABA to 
this receptor leads to the opening of chloride channels, causing hyperpolarization. 
However, because the voltage change depends on the resting potential, GABA might in 
fact cause depolarization. The GABA-b receptor is linked to a potassium channel 
through a guanosine triphosphate binding protein. The hyperpolarization accompanying 
this receptor is slow and long lasting. In the presence of moderate GABA-a blockade, the 
GABA-b mechanism successfully modulates duration of burst discharge. GABA release 
from interneuron terminals may be reduced by activation of GABA-b presynaptic 
receptors. I I 
Glutamate has long been recognized as the pnmary candidate for 
mediating fast excitatory synaptic transmission in the cortex and the hippocampus. Many 
glutamate-receptor SUbtypes exist. The primary iontropic receptors (those associated 
directly with an ion pore) form two major subdivisions, NMDA-preferring receptors and 
non-NMDA receptors.l2 
On most occasions, excitatory postsynaptic potentials in cortical structures are 
produced mainly through activation of non-NMDA receptors. When this channel opens, 
it is permeated primarily with sodium and potassium ions. The NMDA receptor is more 
like GABA-a receptor in its complexity and various sites of modulation. This channel is 
voltage sensitive, being normally blocked by magnesium that binds to a site inside the 
channel. This magnesium blockade is relieved by cell depolarization, as may occur when 
excitatory synaptic input (mediated by non-NMDA receptors) depolarizes the membrane. 
Glutamate binds to the NMDA receptor then opens a channel that is permeable to both 
sodium and calcium. Calcium influx through NMDA channels triggers a number of 
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important processes. Long-term potentiation can be initiated by calcium influx through 
NMDA channels. 13 
The involvement of NMDA in epileptogenesis is suggested by findings of an 
enhanced NMDA component in the EPSP onto hippocampal neurons in kindled tissue 
and by significant NMDA contributions to EPSP's recorded in human epileptic cortical 
and hippocampal neurons. In addition to their voltage and magnesium control, NMDA 
receptors are modulated by glycine (necessary for function), zinc (inhibitory), and 
polyamines. As with the GABA-a receptor, NMDA receptors must be phosphorylated for 
efficient function. The potential importance of NMDA function is illustrated by the 
efficacy of NMDA channel antagonists in blocking late components of burst discharge in 
blocking late components of burst discharge in some models of epileptogenesis. The 
NMDA antagonist amino phosphonovalerate potently blocks initiation but is ineffective 
against already potentiated synaptic responses. This fact suggests that the NMDA 
mechanism is important in kindling of seizure development. 14 
Cell loss is common in the epileptic brain. Glutamate receptors are also important 
in mediating the cell damage so often associated with seizure discharge. Sclerosis is now 
seen as a potential trigger for significant circuitry organization that could further increase 
excitability. One proposed theory on cell loss is the calcium influx, mediated at least in 
part by NMDA receptors, leads to destructive processes in some cells. The NMDA 
antagonists can reduce or eliminate cell damage in ischemia or following high-frequency 
electrical stimulation. Damage is cell-type specific that can explain the high density of 
NMDA receptors on vulnerable neurons. Increases in intracellular calcium mediated by 
NMDA receptors may initiate complex intracellular mechanisms, through second and 
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third messenger systems, that are aspects of normal as well as pathological cell function. 
It has become clear that NMDA activation helps trigger complex changes in central 
nervous system neurons. IS 
Researchers are becoming more interested in other neurotransmitters as 
mechanisms and actions are being discovered. Acetylcholine has long been known to 
excite the central nervous system neurons. The muscarinic receptor actin is mediated by 
a G-protein and generally involves slow changes in membrane potential (depolarizations) 
and increased input resistance, primarily through blockade of a potassium current. 
Similar effects occur with the application of noradrenergic beta-agonists. As a result of 
the action of such drugs, cell firing during membrane depolarization shows less 
adaptation, and hyperpolarizing afterpotentials are significantly reduced. Both effects 
contribute to increased excitability. However, the purpose of intrinsic cholinergic and 
noradrenergic systems in epileptogenesis is not fully known. Other neurotransmitters 
include somatostatin and cholecystokinin, neuropeptides with undetermined roles and 
mechanisms. 16 
Investigations have found that circuitry reorganization occurs as a result of 
seizures in humans. This change involves "sprouting" of axon branches and terminals 
that occur as a result of seizues in human and animal tissue. Sprouting has been seen as 
concurrent loss of cells. This evidence suggests that the sprouting axons "fill in" 
at synaptic sites where cell death has removed the normal presynaptic element. The 
granule cells themselves then expand their recurrent collateral field to occupy the vacated 
synaptic space. 14 
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The excitability of the system could increase as a result of this reorganization 
process which could cause recurrent additional excitatory feedback. If inhibition is 
blocked, the sprouted dentate can be shown to by hyperexcitable. Electrical transmission 
does occur in the central nervous system. These interactions are mediated by gap 
junctions and are seen in both the hippocampus and the neocortex. This coupling 
provides a fast and secure means for synchronizing neuronal populations and could be 
important in the development of synchrony in epileptogenesis. 17 
Clearly not all hyperexcitability and hypersynchrony are the result of chemical 
transmission between cells. Ephaptic interactions, which are defined as synchronizations 
of cellular activity mediated by the flow of current through extracellular space, are 
suspected to be involved in normal cell functioning and in maintaining epileptiform 
activity in the absence of chemical transmission. Changes in extracellular space influence 
current flow and extracellular ion concentrations. Chronically epileptic tissue has shown 
that extracellular calcium concentration decreases during epileptiform bursting activity to 
levels that can not maintain strong synaptic connectivity in the recruitment and 
synchronization of cell discharge during seizures. IS 
The role of glial is considered important in epileptogenesis. Its function is 
thought to be the uptake of potassium from the extracellular space to protect the neuronal 
membranes and maintain appropriate levels of extracellular ion concentration. Glial 
infiltration into epileptic foci is common. This action is thought to be a response to high 
level of activity, because no deficits in glial function have been found to contribute to 
epilepsy. However, researchers have not ruled glial out because in some studies glia have 
shown active properties, such as spiking activity.19 
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Ensemble interaction is an important aspect of epilepsy because of the function of 
large populations of synchronously active neurons during epileptogenesis. If the seizure 
has a focus, than the way its activity is transmitted from focus to follower region is very 
important. Several mechanisms have been discussed concerning how terminals are 
excited. These include accumulation of extracellular potassium and release of excitatory 
transmitter, which proceeds to depolarize terminals. The spread of hyperexcitability is 
limited by the relationship of brain regions to activate those regions that they are 
synaptically coupled to. Another proposed mechanism is the accumulation of 
extracellular potassium ions. Potassium can be redistributed to other brain regions 
through diffusion or by means of glia in a relatively nonspecific manner. The 
extracellular ion buildup may be involved in recruiting neighboring brain areas into the 
hyperexcitability discharging region. Similarly, ephaptic interactions can recruit neurons 
in increasingly wider areas of tissue into synchronized discharge, especially when field 
potentials in the focal regions are large enough to reflect significant extracellular current 
flow. 2o 
One of the most recent concepts to come out of epilepsy research is that of 
permissive gating, especially regarding the granule cells of the dentate gyrus. The dentate 
is a relatively inexcitable part of the hippocampal formation, often generating normal 
activity even in the face of highly abnormal discharge in CAl and CA3 regions. Maximal 
activation of the dentate is now thought to be associated with seizure spread through 
hippocampus and into other brain regions. It is ideally situated to play a gating role 
because of the primary afferent input into the hippocampus is funneled through the 
granule cells. Researchers have speculated that the substantia nigra pars reticulata is 
8 
critical in the generalization of seizure activity. Data suggests that blocking the output of 
the nigra can curtail the development and spread of seizure activity. A similar gating role 
has been postulated for thalamic regions and for superior colliculus.21 
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Treatments of Epilepsy 
Given the relatively complex concepts about how and where seizure activity is generated, 
the blockade of seizure activity can be accomplished in many ways, including anti epileptic drugs, 
surgery, the ketogenic diet, a new device, and a rectal gel. 
One family of medications includes phenytoin, valporic acid, and carbamazepine. These 
drugs interfere with repetitive spiking activity by dampening pathogenic, activity of sodium 
channels. The adverse effects of phenytoin include anorexia, nausea, vomiting, aggression, ataxia, 
cognitive impairment, drowsiness, depression, headache, and paradoxical seizures.4 
Carbamazepine is used for partial and! or secondary generalized seizures. Sodium valporate is 
used as a first line drug for partial and!or secondary generalized, generalized tonic clonic seizures 
without other seizure types, typical absence, myoclonic absence, atonic, tonic and most childhood 
absence seizure types. Carbamazepine has adverse effects including diploia, dizziness, sedation, 
and induction of liver enzymes.4 
Ethosuximide, trimethadione, and methosuximide appears to target low threshold calcium 
specifically, acting preferentially on cells whose activation pattern depends predominantly on 
these channels. Ethosuximide, another antiepileptic drug used specifically for petit mal epilepsy, 
acts on this channel to prevent a rise of a burst of action ~otentials that can develop when these 
channels open to admit calcium. ( other book) The thalmic role in producing spontaneous rhythmic 
activity, dependent on low threshold calcium conductances, is believed to be specifically 
antagonized by such drugs. 
Tiagabine and vigabatrin enhance cerebrospinal levels of GAB A by interfering with 
reuptake and degradation of GABA, respectively. 1 Tiagabine has been deemed effective in partial 
and secondarily generalized seizures. The adverse effects of Tiagabine include dizziness, asthenia, 
and tremor. 2 Vigabatrin is not limited to partial seizures. It has emerged as a potential 
first-choice AED against infantile spasms. The most common adverse effects of vigabatrin 
include drowsiness, dizziness, ataxia, tremor, amnesia, depression, weight gain, and hyperactivity 
in children. Recently visual field constriction, bilateral optic disc pallor, and subtle peripheral 
retinal atrophy have been linked to vigabatrin.2 
Lamotrigine, like phenytoin and carbamazepine, blocks sodium channels. 1 This sodium 
channel blockade results in inhibition of glutamate release. There is increasing evidence that 
lamotrigine is effective against generalized seizures, particularly absence seizures.2 Some of the 
most common dose-related adverse effects include dizziness, sedation, headache, diplopia, and 
ataxia. 2 
Another antiepileptic medication is Gabapentin. It is the first AED to be eliminated 
entirely by the kidneys.2 Gabapentin is designed as a centrally acting GABA agonist, yet it 
apparently does not interact with GABA receptors nor does it interfere with GABA metabolism. 
It instead interacts with a novel binding site, which contains a specific protein found only on 
neurons in the central nervous system. This protein is found in highest density in areas of the 
neocortex that are rich in synapses containing the excitatory neurotransmitter glutamine. 1 
Adverse effects of gabapentin include somnolence, dizziness, ataxia, behavioral problems, weight 
gain, and movement disorders. Serious adverse events have been exceedingly rare? 
T opiramate has been identified as having at least three mechanisms of action. These 
include state-dependent blockade of sodium channels, potentiation of gamma-aminobutyric 
acid-mediated neuroinhibition, and blockade of glutamate-mediated neuroexcitation. This drug is 
effective in refractory partial seizures in adults, partial seizures in children, and generalized 
tonic-clonic seizures in children and adults. The most common adverse efects of topiramate 
include sedation, problem with concentration and word finding, decreased appetite, and weight 
loss. Nephrolithiasis has occurred in 1.5% ofpatients.2 
Surgery is gaining increasing popularity as a method of treating patients who have focal 
seizures unresponsive to anti convulsant therapy. EEG recording with videotaping is important in 
localizing the site. Subdural electrodes are often used to determine the extent of the epileptogenic 
activity accurately. Other tests are used to assist in localization of seizure foci . These include 
neuropsychologic evaluations, the Wad a test, SPECT, PET, and MRI studies. Temporal lobe 
resection is the most common surgery performed. 2 Although not always successful, surgery can 
relieve patients of the burden of medication and general dysfunction. 
The ketogenic diet was frequently used for the treatment of intractable epilepsy before the 
discovery of the newer antiepileptic medications. The mode of action is unknown, but the seizure 
control may be correlated directly with elevated levels of beta-hydroxybutyrate and acetoacetate 
that result from ketosis. 3 The ketogenic diet supposedly simulates the metabolism of a fasting 
body, which has been considered since biblical times an effective means to control seizures. This 
fast was then coupled with a high-fat diet in order to cause acidosis, ketosis, and increased levels 
of uric acid levels in the blood and urine without causing starvation.4 
On July 16, 1997, the US Food and Drug Administration approved the first implantable 
device to reduce the number of seizures. It is seen as the pacemaker for the vagus nerve, whose 
stimulation produces an anti-epileptic effect by modulating the abnormal neuronal firing 
associated with seizures. When implanted, the device not only provides stimulation to the vagus 
nerve at regular intervals, but the patient also has a magnet that can stimulate the nerve at the 
onset of a seizure. The device is well tolerated and accepted by patients. 
In July of 1997, Diastat was approved by the FDA. This drug is a gel formulation for 
rectal administration of the anti epileptic diazepam to stop clustered or prolonged seizures in 
progress. It is the first therapy prepared to be easily given in this manner ever to become 
available for in-home use in bringing potentially dangerous bouts of increased seizure activity 
under control. This drug will be able to give caregivers a greater sense of control. Trips to the 
emergency room are able to be greatly eliminated during bouts of unstoppable seizures. 
Somnolence and headaches were the tow most frequently reported side effects in these studies.3 
Epilepsy research is at a fast pace. Therefore, as more is learned about the functions, and 
malfunctions, of the brain, more is done in developing mediations designed to fit specific problems 
and patients. These newer medications are generally better tolerated by patients as they have 
fewer side effects. However, because of ethical obligations in test design, most new medications 
are only approved for add-on therapy. Neurologists, researchers, and patients all remain all 
remain hopefully that one day all epileptics will be able to say that they are seizure-free. 
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Sexuality in Epilepsy 
Sexual behavior requires a normally functioning neuroanatomic substrate, which includes 
the frontal lobe and limbic structures, as well as adequate levels of hypothalamic, pituitary, and 
gonadal hormones. This behavior can be disturbed in epilepsy.1 
Sexual behavior can be divided into two main components, desire and arousal. Desire 
reflects the individual's psychological heath, cultural expectations, past sexual experiences, and 
requires salient sexual stimuli. Hormones are also required to support sexual desire. Those 
hormones include estrogen, progesterone, testosterone, lutenizing hormone, follicle stimulating 
hormone, and prolactin.2 
Arousal is defined as the ability to respond to an appropriate stimuli with a series of 
stereotyped vascular, neural, and muscular responses. A normal sexual response requires an 
intact, functioning cerebral cortex, spinal cord, and autonomic nervous system. Genital structures 
must be normal. Hormones also play an important role.3 
Sexual dysfunction was first described in people with epilepsy in 1956. Thirty to sixty 
percent of men with epilepsy have some disorder of desire or arousal, most often impotence. In a 
study conducted in 1985, 21 percent of men studied had never experienced sexual intercourse 
despite having the opportunity to do so. Also, in this same study at least one third of sexually 
active subjects had difficulty achieving and maintaining an erection or ejaculating.4 
In epileptic women, there is a high incidence of dyspareunia, vaginismus, and arousal 
insufficiency. One third of women described themselves as dissatisfied with their overall sexual 
function, compared with eight percent of the normal population. S 
There are a number of potential mechanisms by which sexuality may be disturbed in 
people with epilepsy. Psychosocial deficits, such as restricted social opportunities and poor 
self-esteem, limit the opportunity for normal sexual interactions. Poor disease acceptance is 
associated with sexual dysfunction in other chronic illnesses, and may contribute to impaired 
sexuality in epilepsy. However physiological mechanisms may be more relevant than 
psychological variables. Disruption of cortical regions mediating sexual behavior, either by fixed 
lesions or by epileptiform discharges, could influence sexual desire and arousal. Changes in 
hormones supporting sexual behavior occur in epilepsy, both because of seizures and antiepileptic 
drugs. Antiepileptic drugs have direct effects on conical regions mediating sexuality and may also 
cause sexual dysfunction by secondary effects on reproductive hormones. 6 
Psychosocial disability can adversely impact sexuality in men and women with epilepsy. 
Individuals with epilepsy are susceptible to poor self-esteem. Recurrent seizures may lead to a 
sense of vulnerability and helplessness, impairing the capacity to form healthy, nurturing 
relationships. Having epilepsy may limit social development, particularly for patients with 
frequent seizures who have restricted access to usual educational and occupational experiences. 
Individuals also express concern that sexual activity will precipitate a seizure, particularly those 
whose seizures are sometimes triggered by hyperventilation or physical exertion.? 
Several clinical observations suggest that dysfuntion in limbic structures predisposes to 
sexual dysfunction. Sexual dysfunction usually arises after the onset of seizures. It is most 
common in individuals with localization-related epilepsy, particularly those whose seizures arise 
from the amygdala and hippocampus. Reports show that sexual dysfunction improves after 
temporal lobectomy for medically intractable seizures. 8 
Alterations in pituitary and gonadal hormones can negatively impact sexual behavior in 
people with epilepsy. In both epileptic men and women, interictallevels of prolactin are elevated 
because of seizures. Elevated prolactin is one of the most frequent causes of impotence in 
otherwise healthy males. The free fraction of sex steroid hormones may be reduced in individuals 
with epilepsy. Low levels of free testosterone have been associated with disorders of sexual 
desire and ,amusaLin men.9 
Sexual dysfunction may also be a consequence of ictal alterations in neurotransmitters, 
including gamma amino-butyric acid (GABA), opioids and serotonin. In a study using rabbits, 
elevations in GABA inhibit sexual behavior. Serotonin agonists specific to one receptor subtype 
inhibit sexual desire and sexual arousal in rats. 10 
Antiepileptic drugs affect sexual behavior by at least two mechanisms-alterations in 
hormone metabolism and binding, and by direct cortical effects. They may induce or inhibit the 
hepatic microsomal enzyme system and alter metabolism of sex steroid hormones. Many 
antiepileptic drugs also induce production of sex hormone binding globulin (sHBG), a binding 
protein for steroid hormones. Increased binding reduces the free, biologically active traction. 
These two mechanisms cause a reduction in the free level of steroid hormones. Antiepileptic 
drugs are also associated with elevations in prolactin and gonadotropins. Antiepileptic drugs may 
act as suppressants of sexual behavior. Diminished libido and arousal were described in 12% of 
men beginning an anti epileptic drug. 11 
AED's do not cause all sexual deficits observed in people with epilepsy. First, sexual 
dysfunction generally arose with the onset of epilepsy- prior to treatment. Sexual deficits may 
improve when seizures are controlled, even if a higher dose of anti epileptic drug is required or a 
temporal lobectomy is performed. 12 
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Fertility Problems in Epilepsy 
Women with epilepsy have fewer children than women in the general population. Their 
fertility rate is 25 to 33 percent lower than the average. Social pressures on women with epilepsy 
to refrain from having children may be a factor in their lower rate of childbearing. However, 
studies reveal that biological factors rather than social factors play a role in the higher rates of 
infertility in women with epilepsy.l 
Menstrual irregularities are seen more often in women with epilepsy than in women who 
do not have the disorder. Research has demonstrated a high proportion of reproductive and 
endocrine disorders in women with epilepsy, which can affect their ability to conceive or carry a 
child to term. 2 
Menstrual abnormalities and gynecologic syndromes such as polycistic ovaries, 
hypogonadotropic and hypergonadotropic hypogonadism, oligomenorrhea, and amenorrhea are 
more common in women with epilepsy. A probable cause for this is the effect of antiepileptic 
mediation on the hypotharnic-pituitary axis, or indirectly through alterations in the metabolism of 
sex steroids. Women with temporal lobe epilepsy are particularly prone to anovulation. 
Dysfunction of the limbic cortex, which is extensively interconnected with the hypothalamus, 
appears to alter the release of hypothalrnic hormones and pituitary gonadotropins, resulting in 
anovulation.3 
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Catamenial Epilepsy 
Catamenial epilepsy is defined as a cyclic increase in epileptic attacks which coincide with 
menses. In early times, these changes were attributed to the moon. In 1885, Gowers first 
examined the association of menses and epilepsy. 1 
Catamenial epilepsy is observed in 10 to 70% of women with epilepsy. This wide range in 
incidence is due to the lack of a more specific definition of catamenial epilepsy. 70% of women 
claim that their seizures are exacerbated by menstruation. However, the strict definition states 
that catamenial epilepsy is epilepsy that occurs at or worsens around menstruation, and can be 
demonstrated in 12% of women with epilepsy. These menstrual exacerbations occur with all 
types of seizures. 2 
Several investigators show that even nonepileptic women exhibit minor EEG fluctuations 
during the menstrual cycle. In 1942, Dusser de Barenne and Gibbs discovered cyclical 
background slowing during two menstrual phases: the time of menstrual flow and the time of 
ovulation. Other studies reveal a drop in the amplitude of the EEG during the premenstrual and 
menstrual phases.3 
Catamenial epilepsy is believed to result from cyclic alterations in both ovarian hormone 
levels and drug metabolism. In women with catamenial epilepsy, seizures frequently start at or 
shortly after menarche. Many of these women show increased electroencephalographic activity 
during menstruation. Seizure threshold is increased by progesterone and decreased by estrogen, 
an effect presumably caused by alterations in brain excitability. Frequency of seizure activity has 
been shown to increase during two specific times in the menstrual cycle. The first corresponds to 
the rapid decrease in progesterone just before menses and the second to the elevation of estrogen 
before ovulation. An increase in frequency is also seen during anovulatory cycles when 
progesterone levels are relatively low. Menopause or oophorectomy may lead to significant 
improvement in epilepsy.4 
Pregnanolone, a main metabolite of progesterone, modulates the major inhibitory 
neurotransmitter, gamma-aminobutyric acid (GABA), and augments the GABA-induced chloride 
current in hippocampal neurons. It is hypothesized that endogenous neurosteroids including 
pregnanolone, may decrease when progesterone concentrations fall before menstruation, reducing 
the inhibitory effets of GABA and causing seizure exacerbation. 5 
A 1986 study by Rosciszewska, Bunter, Guz, and Zawisza showed that seizure incidence 
during the menstrual cycle is connected with a deficit of progesterone rather than elevated 
oestrogen levels. In the study, the lowest number of seizures was noted when progesterone 
reached its highest level. The "protective effect" of progesterone on brain activity in women can 
be confirmed by the use of synthetic progesterone in the therapy for catamenial epilepsy. A 
related study showed a reuction of seizure frequency in 7 of 10 women treated with 
medroxyprogesterone.6 
Females with so-called catamenial epilepsy had premenstual tension more frequently. This 
difference is connected with greater endocrine disturbances and changes in water-electrolyte 
balance. Thus, the effect of this syndrome on serum concentration of anticonvulsants during 
premenstrual phase can not be neglected. 7 
A new controversy has erupted on the radical remedy of bilateral oophorectomy in order 
to treat catamenial epilepsy. It is seen as a last result in patients with epilepsy that can not be 
controlled by any of the appropriate and accepted treatments. A case in Liverpool studied a 
woman who had tried hormonal treatment, regular anti epileptic drug treatment, and combination 
anti epileptic drug treatment. When she became pregnant, she experienced no seizures until after 
delivery. Finally a total abdominal hysterectomy and bilateral salpingooophorectomy was 
performed. She has had no seizures since the surgery. g Other doctors argue that this treatment 
was too radical. They believe that epilepsy should be fully identified by the specific syndrome 
and have the accepted treament possibilities exhausted before these unsubstantiated remedies are 
used.9 
Menstrual abnormalities and gynecologic syndromes such as polycystic ovaries, 
hypogonadotropic and hypergonadotropic hypogonadism, oligomenorrhea, and amenorrhea are 
more common in women with epilepsy. A probable cause for this is the effect of antiepileptic 
medication pn the hypothamic-pituitary axis, or indirectly through alterations in the metabolism of 
sex steroids. Women with temporal lobe epilepsy are particularly prone to anovulation. 
Dysfunction of the limbic cortex, which is extensively interconnected with the hypothalamus, 
appears to alter the release of hypothalmic hormones and pituitary gonadotropins~ resulting in 
anovulation. 10 
Medication levels are known to fluctuate at different times throughout the cycle. 
Decreased serum levels of phenytoin demonstrated during menses in women with catamenial 
epilepsy correlate with increased seizure activity. "The decrease in estrogen and progesterone at 
menstruation is believed to stimulate the release of hepatic monoxygenase enzymes which 
accelerates the risk" of seizures. Recommended treatment of catamenial epilepsy includes 
measurement of serum levels of anticonvulsants during times of seizure exacerbation. Sometimes 
an altered dosing schedule is recommended for seizure control. I I 
Some investigations have shown that progesterone therapy is beneficial. In addition to 
antiepileptic properties, progesterone may work by suppressing gonadotropin release whic~ in 
tum, lowers estrogen levels. The effects of combined oral contraceptives on frequency of seizure 
have been inconsistent, with seizure exacerbation occurring on pill free days. Uninterrupted 
combined use of oral contraceptives or the progestin-only oral contraceptive may be preferable in 
women with epilepsy as they result in continuous progestin exposure. Because of the decrease of 
efficacy of oral contraceptives in patients with epilepsy receiving anti-convulsant therapy due to 
altered metabolism of the contraceptive steroids, a higher dose of oral contraceptive pills are 
recommended. 12 
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Epilepsy and Pregnancy 
Pregnancy in epileptic women is a growing concern in society. Women with epilepsy who 
become pregnant are frequently considered to have a high risk of an adverse outcome. 1 
Congenital abnormalities are increased two to three times over the normal population.2 Not only 
are the seizures themselves harmful to the child, but also the anti-epileptic drugs, AED's, prove a 
threat to the child. Nekane et al., 1980, studied the incidence of newborn malformations born to 
epileptic women. The study revealed that congenital malformations were least in newborns of 
women not taking medication, but remaining seizure free. The highest prevalence was among 
women who both had seizures and took AED's. Women having seizures but not taking medicine 
and women without seizures but taking medication occupied an intermediate position. In addition 
to the seizures and the medication, the changing metabolism of the mother can prove challenging 
to the doctor. 3 
Many women experience changes in drug metabolism during pregnancy. 25-30% of 
women experience an increase in seizure frequency and severity during pregnancy.4 Because 
there is an increase in circulating serum proteins, a decrease occurs in the blood level of free, 
active drug. Therefore, physicians recommend that the free rather than total, serum drug level 
should be monitored in pregnant patients. The normal increase in extracellular fluid may also 
cause fluctuations in anti epileptic drug levels. Other factors that may suppress drug levels are 
delayed gastric emptying and hyperemesis. Physicians also cite noncompliance with medications, 
hyperventilation, dilutional hypocalcemia and hyponatremia, emotional stress and sleep 
deprivation as factors contributing to seizure frequency and intensity increases. 5 
The seizure itself can be harmful during pregnancy. A tonic-clonic seizure can result in 
blunt abdominal trauma often causing premature rupture of membranes. 6 These seizures have also 
caused fetal intra-cranial hemorrhage, miscarriage, fetal neonatal, and prenatal death.7 Also, fetal 
heart rate decreases during a seizure. If the mother has a seizure in the first trimester there is an 
increased rate of spontaneous miscarriage and an increased risk in fetal malformations. These 
effects are likely due to transient fetal hypoxia and acidosis secondary to altered uteroplacental 
circulation. 8 
A decrease in fetal viability is seen in children of epileptic mothers. These infants are also 
more likely to have lower Apgar scores. A decrese in fetal growth is also apparent in infants of 
epileptics. These children are more likely to be small for gestational age. Seven to ten percent 
meet the criteria for low birth weight. Also four to eleven percent are born premature.9 
An increased risk offetal bleeding is seen in children exposed to AED's in utero. 
Phenytoin, primodine, and phenobarbital are known to inhibit transport of vitamin K across the 
placenta. Therefore, there is a decrease in fetal vitamin K-dependent clotting factors (II, VII, IX, 
X). Fetal hemorrhage within 24 hours after birth is a probable outcome. Treatment for these 
infants includes additional vitamin K, and fresh frozen plasma to correct the coagulopathy.lo 
Scientists have targeted AED's as having teratogenic effects. All AED's have been found 
to be teratogenitic.11 The greatest risk of congenital malformation comes with exposure to AED's 
during the third to eighth week after conception.12 Minor digital and rnidfacial abnormalities are 
seen in 5-30% of infants of women with epilepsy.13 Other malformations include neural tube 
defects and heart defects.14 Polytherapy and higher drug levels are associated with an increased 
risk of malformations. 15 Cardiac defects are linked to phenobarbital, phenytoin, and primodine. 
Trimethodione is not recommended for a pregnant mother because it produces severe birth 
defects, mental retardation, and developmental delay in about 50% of offspring. 16 
Of all the AED's, the hydantoins are most commonly associated with adverse pregnancy 
outcomes. Approximately 1 in 500 pregnancies have had fetal exposure to phenytoin, the most 
common hydantoin. Fetal hydantoin syndrome occurs in 10-30% of exposed pregnancies. 
Common symptoms of the syndrome include growth deficiency, central nervous system 
dysfunction (e.g., mental retardation), craniofacial anomalies, increased risk of major 
malformations and nail/digit hypoplasia. School and learning problems, developmental problems, 
and physical abnormalities, such as nail hypoplasia and growth failure, are significantly higher in 
those affected by the syndrome. Increased risk for recurrence in subsequent pregnancies is 
shown by studying families with two exposed children. In this study, either both or neither were 
affected. Children exposed to phenytoin had an average global intelligence quotient (IQ) 10 
points lower than controls. 17 
Carbamazepine is another AED shown to have teratogenicity. In one study 50 women 
took carbamazepine as monotherapy. 35 gave birth to exposed infants with the following 
abnormalities: craniofacial defects (11%), fingernail hypoplasia (26%), and developmental delay 
(20%). The syndrome causing these results was named "fetal carbamazepine syndrome" . 
Children with this syndrome also exhibit slow development and low IQ scores. In a dosage study, 
carbamazepine given at the highest dosage caused a significant decrease in fetal body weight, a 
2.9-fold increase in fetal resorptions, and a 29% decrease in maternal weight compared to 
controls. Soft tissue and skeletal malformations increase sixfold. 18 
Valporic Acid, VP A, also has teratogenic effects. It has been linked to spina bifida with a 
1-2% risk with maternal use. Fetal valparoate syndrome has been described. Symptoms include 
craniofacial anomalies, with minor abnormalities in ear shape or position being common, 
congenital heart defects. Developmental delay occurs in more than two-thirds of the cases 
exposed to monotherapy. Recently it has been reported that neurologic performance is still 
impaired at 6 years of age. 19 
Fetal benzodiazepine syndrome is frequent in children born to mothers taking 
benzodiazepines. Frequent symptoms include short nose with a low nasal bridge, and uptilted 
nose and epicanthic folds . Other symptoms include slanting eyes, low-set or abnormal ears, and a 
hypoplastic mandible. Children also had delayed neurodevelopment. Infants exposed to both 
VP A and benzodiazepines had more pronounced abnormalities than those receiving monotherapy. 
In one study, 64 out of.80 infants receivin~ benzodiazepines in utero had sedation and withdrawal 
symptoms at birth. Fifty had no developmental anomalies, but 6 had conditions consistent with 
teratogenicity. 20 
Primo dine and phenobarbital are associated with fetal anomalies similar to those 
associated with other AED's. Symptoms include both pre- and postnatal growth failure, 
hirsutism, microcephaly, mental retardation, hypoplastic nails, and craniofacial anomalies such as 
short nose, ptosis of the eyelids, low-set ears, and CP. Prenatal exposure to phenobarbital 
exposure has been shown to lower verbal inteligence score in adult men tested in a recent study.21 
Trimethadione is contraindicated in pregnancy. It produces severe birth defects, mental 
retardation, and developmental delay in fifty percent of offspring. Therefore, a woman of 
childbearing age should not take trimethadionine.22 
The teratogenicity of the newer antiepileptic drugs are not well documented. However, 
some information is obtained by the preclinical studies. F elbamate did not show birth defects in 
rats or rabbits. Gabapentin at high doses was toxic to rodent fetuses . Delayed ossification of 
bones was also noticed. Lamotrigine is a weak inhibitor of dihydrofolate reductase, and antifolate 
activity is associated with teratogenicity. Topoiramate showed growth retardation and limb 
agenesis. Tigabine has shown growth retardation in animal studies.23 
The risk of the child of an epileptic having epilepsy is increased to two to four percent 
compared with one percent for the general population. Also a significant risk of fetal death is 
present, although this risk has been minimized with the growth of knowledge on the subject. 
Sedation may occur in the infant if it injests phenobarbital from breast feeding. Most mothers 
taking AED's can breast feed .24 However, phenobarbital or primidone should be used with 
caution by nursing women. Women taking gabapentin, topiramate, or tiagabine should nurse only 
when the benefits outweigh the risks. Mothers taking lamotrigine are not recommended to breast 
feed. The manufacturer of felbamate suggests it be used with caution in nursing women.2S 
Multiple antiepileptic drugs have been shown to increase risk profiles. "When 
carbamazepine, phenobarbital, and VPS are combined with or without phenytoin, 58% of infants 
have birth defects. ,,26 This is higher than with outher three- to four-drug combinations, suggesting 
metabolic interactions. VP A inhibits epoxide hydroxylase, which increases the presence of 
epoxide metabolites of aromatic AED's. 
Maternal folate concentrations normally decline during pregnancy. AED use may cause 
further decreases, thereby increasing the risk of folate deficiency. In one study, phenytoin and 
phenobarbital produced the greatest decrease in serum folate. Serum folate and RBC folate 
concentrations were significantly lower in women having spontaneous abortions or children with 
major malformations compared with those with normal outcomes. Pregnant women taking 
multiple anticonvulsants tended to have an increased risk for folate deficiency compared with 
those receiving monotherapy. Women were more likely to have an adverse pregnancy outcome 
when serum folate was less than 4 microgram! mL before pregnancy.27 Phenytoin, carbamazepine, 
phenobarbital, lamotrigine, and possibly valporate have been found to have antifolate activity.28 
Findings in multiple studies showed that all women taking AED's should also receive 
supplemental folic acid. 29 
Oral contraceptives reduce both serum folate and RBC folate levels. Serum folate 
concentrations decr~ase with chronic use of oral contraceptives and normalize within 3 months 
after discontinuing the oral contraceptive. Epileptic women taking oral contraceptives and AED's 
may be at higher risk, since they are taking more than one folate-lowering drug, and may 
experience contraceptive failure caused by enzyme-inducing AEDs. More studies are needed in 
order to see the true effects.30 
Reactive epoxide metabolites may be responsible for AED-induced teratogenicity. 
Phenytoin, carbamazepine, phenobarbital, felbamate, and lamotrigine may be metabolized to form 
epoxides. Adding valporic acid to any of these AED's may increase the risk, because this drug 
inhibits epoxide hydrolase, thereby increasing epoxide concentrations. Folate deficiency could 
further increase epoxide concentrations of aromatic AED's .3 \ AED's may be particularly 
dangerous in women predisposed to give birth to infants with neural tube defects. These women 
may not utilize folate as efficiently as other women and AED use diminishes serum folate 
concentrations.32 
Physician recommendations for epileptic mothers include the following: 
1. Use a first-choice antiepileptic drug for seizure type and epilepsy syndrome. 
2. Use the AED as monotherapy and at the lowest dose possible that protects against 
tonic-clonic seizures. 
3. Monitor plasma AED levels monthly and, if possible, obtain free or unbound levels. 
4. Avoid polytherapy, especially combinations of val pro ate, phenobarbital and 
carbamazepine. 
5 . Avoid valporate and carbamazepine when there is a family history of neural tube 
defects. 
6. Begin folate supplementation in the preconception period. 
7. When using valporate, avoid high plasma levels and divide the dose over three to four 
administrations per day.33 
In addition to the above, physicians often recommend women delaying pregnancy until 
seizures are adequately controlled. Also, amniocentesis and level II ultrasound at 16-18 weeks 
should be preformed to check for neural tube and cardiac malformations. Vitamin K should be 
given to mother from her 36th week on and also given to the baby at birth.34 Some physicians 
also recommend a gradual discontinuation of antiepileptic drugs if a woman is seizure-free with a 
normal encephalogram for at least two years.35 
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Sudden Death and Epilepsy 
Sudden unexpected, unexplained death (SUD) is more common in patients with epilepsy 
compared with the general population. The mechanism is unclear, but there are several theories. 
These include cardiac tachy- or bradyarrhythmias related to paroxysmal autonomic dysfunction, 
respiratory arrest and neurogenic pulmonary oedema, and events occuring in connection with 
overt or subclinical seizures. Low or undetectable post-mortem blood concentrations of 
antiepileptic drugs has been a frequent finding in cases of SUD. Although these reports have been 
questioned based on their methodology, they have raised questions regarding sudden drug 
withdrawal or non-compliance as precipitating factors for SUD. I 
The anitepileptic drugs carbamazepine and phenytoin are sodium-channel blockers with a 
membrane stabilizing effect in the central nervous system as well as in the cardiac conduction 
system and myocardium. Carbamazepine may induce cardiac bradyarrhythmias, which has caused 
safety concerns, and phenytoin has been used and classified as an antiarrhythmic drug. A sudden 
withdrawal of such cardioactive drugs might theoretically induce both direct and indirect cardiac 
changes of relevance for SUD unrelated to seizure activity. 2 
A recent study demonstrated that abrupt withdrawal of anti epileptic treatment reduced 
heart-rate variability suggesting an altered autonomic modulation, which in other patient 
populations has been associated with increased mortality. The withdrawal of these drugs induced 
an expected reduction in bradycardias in a subgroup of patients. However, there was also an 
unexpected 10-fold increase in ventricular premature beats in some patients suggesting increased 
electrical instability. Since reduced heart-rate variability signals a state of increased electrical 
vulnerability and ventricular premature beats might trigger life-threatening ventricular arrhythmias 
the findings of the experiment point to two important factors that might contribute to an increased 
risk for sudden death during abrupt withdrawal of sodium-channe1-blocking antiepileptic drugs 
even in the absence of seizures.3 
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Memory and Epilepsy 
Cognitive dysfunction has long been known to accompany seizure activity. There are 
many different factors affecting memory. These include the underlying cause of the epilepsy, 
seizure type, frequency and severity of seizures, undetected seizures, psychosocial factors such as 
mood and expectations and anti epileptic drugs. 1 It is agreed that memory function improves as 
the control of seizure improves.2 
Structural cerebral abnormalities which underlie the epileptic focus often directly cause 
cognitive dysfunction. However, epileptic foci arising distant from those brain structures known 
to be involved in learning and memory may also be associated with disorders of learning and 
memory. Excision of epileptic foci was shown to improve cognitive function in experimental 
models in primates.3 
It appears that seizure activity incrementally causes an indiscriminate and widespread 
induction of long-term potentiation, consuming and thereby reducinE overall hipJ>ocampal 
plasticity available for information processing. Because the seizure activity appears to consume 
the synaptic J>lastici~ available in otherwise healthy brain tissue making the formation of new 
memories is disrupted, and may represent a mechanism by which cognitive function is impaired in 
epileptic humans.4 
The physiological and cognitive effects can be modulated by NMDA receptor-associated 
channel blockade. This suggests that future therapeutic strategies directed towards the 
preservation of hippocampal synaptic plasticity may prove effective in the attenuation of 
epilepsy-associated cognitive impairment. Unfortunately, presently available drugs active at the 
NMDA receptor site (such as ketamine) can only be used effectively where seizure activity can be 
precisely predicted, as in electroconvulsive therapy. S 
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